Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sugars × Dermatologic × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8 Genitourinary 4 Thoracic 3 Plasma cell 3 Head & Neck 3 Lymphoid 2 Gastrointestinal 2 Tumor-Agnostic 1 Other neoplasm 1 Other hematologic neoplasm 1 Other 1 Gynecologic 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 97 Nivolumab 97 Ipilimumab 97 aldesleukin 65 Cyclophosphamide 59 fludarabine phosphate 43 Interleukin-2 40 trametinib 30 Temozolomide 29 Dacarbazine 29 dabrafenib 27 Bevacizumab 27 fludarabine 25 Radiotherapy 25 sargramostim 24 Vemurafenib 24 incomplete Freund's adjuvant 23 Radiosurgery 23 Paclitaxel 18 binimetinib 17 Carboplatin 17 Aminolevulinic Acid 17 encorafenib 16 atezolizumab 16 Peripheral Blood Stem Cell Transplantation 16 cobimetinib 15 Mycophenolic Acid 15 HhAntag691 15 Biopsy 15 Sorafenib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Dana-Farber Cancer Institute

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡